Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease

Zhangqin LI; Qi HUANG; Yinglei MIAO

doi:10.12259/j.issn.2095-610X.S20240223

Volume 45 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(2): 160-165

Zhangqin LI, Qi HUANG, Yinglei MIAO. Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease[J]. Journal of Kunming Medical University, 2024, 45(2): 160-165. doi: 10.12259/j.issn.2095-610X.S20240223

Citation:

Zhangqin LI, Qi HUANG, Yinglei MIAO. Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease[J]. Journal of Kunming Medical University, 2024, 45(2): 160-165. doi: 10.12259/j.issn.2095-610X.S20240223

Citation:

PDF( 557 KB)

Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease

doi: 10.12259/j.issn.2095-610X.S20240223

Dept. of Gastroenterology，The 1st Affilited Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2023-12-29
Publish Date: 2024-02-25

Abstract

Abstract

Inflammatory Bowel Diseases （IBD） is a class of genetically related diseases caused by multiple genes and environmental factors that accelerate the disturbance of the immune-gut-microbiome axis. Lesions often involve multiple organs and systems. Biological agents are an important means of treating IBD and its extraintestinal manifestations. Current studies suggest that biologics can bring benefits to patients, but paradoxical skin lesions, joint lesions, and ocular lesions appear during the treatment. Diseases, pulmonary lesions and other manifestations or lesions are easily ignored in clinical practice, thereby delaying the patient's condition and affecting the patient's quality of life. Therefore, by summarizing the clinical characteristics and diagnosis and treatment experience of contradictory extraintestinal manifestations in the current application of biological agents, this review aims to improve the understanding of clinicians, identify this clinical manifestation early, and avoid delaying the patient's condition.
- Inflammatory bowel diseases,
- Paradoxical extraintestinal manifestations,
- Biologics

FullText(HTML)

References(50)

References

[1]	Baumgart D C,Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease[J]. The New England Journal of Medicine,2021,385(14):1302-1315. doi: 10.1056/NEJMra1907607
[2]	Toussirot É,Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview[J]. RMD Open,2016,2(2):e000239. doi: 10.1136/rmdopen-2015-000239
[3]	Harbord M,Annese V,Vavricka S R,et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J]. Journal of Crohn’s & Colitis,2016,10(3):239-254.
[4]	Marzano A V,Borghi A,Stadnicki A,et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology,clinical features,and therapy[J]. Inflammatory Bowel Diseases,2014,20(1):213-227. doi: 10.1097/01.MIB.0000436959.62286.f9
[5]	Antonelli E,Bassotti G,Tramontana M,et al. Dermatological manifestations in inflammatory bowel diseases[J]. Journal of Clinical Medicine,2021,10(2):364. doi: 10.3390/jcm10020364
[6]	de Gannes G C,Ghoreishi M,Pope J,et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions[J]. Archives of Dermatology,2007,143(2):223-231.
[7]	Notley C A,Inglis J J,Alzabin S,et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells[J]. The Journal of Experimental Medicine,2008,205(11):2491-2497. doi: 10.1084/jem.20072707
[8]	Ma H L,Napierata L,Stedman N,et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells[J]. Arthritis and Rheumatism,2010,62(2):430-440. doi: 10.1002/art.27203
[9]	Schäffler H,Blattmann T,Findeisen A,et al. PAPA-Syndrom mit Morbus Crohn und primär sklerosierender Cholangitis/Autoimmunhepatitis-Overlap-Syndrom[J]. Der Hautarzt,2019,70(2):116-122. doi: 10.1007/s00105-018-4312-5
[10]	Cullen G,Kroshinsky D,Cheifetz A S,et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature: Anti-TNF-induced psoriasis in inflammatory bowel disease[J]. Alimentary Pharmacology & Therapeutics,2011,34(11-12):1318-1327.
[11]	Fréling E,Baumann C,Cuny J-F,et al. Cumulative incidence of,risk factors for,and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: A 14-year experience[J]. The American Journal of Gastroenterology,2015,110(8):1186-1196. doi: 10.1038/ajg.2015.205
[12]	Hu J Z,Billings S D,Yan D,et al. Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris[J]. Journal of the American Academy of Dermatology,2020,83(1):71-77. doi: 10.1016/j.jaad.2020.01.006
[13]	Cleynen I,Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD[J]. Nature Reviews Gastroenterology & Hepatology,2012,9(9):496-503.
[14]	Greuter T,Navarini A,Vavricka S R. Skin manifestations of inflammatory bowel disease[J]. Clinical Reviews in Allergy & Immunology,2017,53(3):413-427.
[15]	Rahier J-F,Buche S,Peyrin-Biroulet L,et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy[J]. Clinical Gastroenterology and Hepatology:The Official Clinical Practice Journal of the American Gastroenterological Association,2010,8(12):1048-1055. doi: 10.1016/j.cgh.2010.07.022
[16]	Flendrie M,Vissers W H P M,Creemers M C W,et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study[J]. Arthritis Research & Therapy,2005,7(3):R666-676.
[17]	Chang Y-C,Yang H-J. Successful management of tumor necrosis factor-alpha inhibitor-induced Sweet syndrome in a patient with ulcerative colitis: A case report[J]. Int. Journal of Clinical Pharmacology and Therapeutics,2022,60(01):46-51. doi: 10.5414/CP204088
[18]	Lu S,Yao J,Zhi M. Therapeutic effect of ustekinumab on patients with extra-intestinal manifestations of Crohn’s disease[J]. Expert Review of Gastroenterology & Hepatology,2023,17(4):379-384.
[19]	Nguyen E D,Gabel C K,Kroshinsky D. Assessing the incidence of skin and soft tissue infection in patients on biologics[J]. Journal of the American Academy of Dermatology,2021,85(3):604-610. doi: 10.1016/j.jaad.2020.03.128
[20]	Ezzedine K,Visseaux L,Cadiot G,et al. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study[J]. The Journal of Dermatology,2019,46(4):322-327. doi: 10.1111/1346-8138.14816
[21]	Kolios A G A,Biedermann L,Weber A,et al. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab[J]. The British Journal of Dermatology,2018,178(2):551-555. doi: 10.1111/bjd.15631
[22]	Tadbiri S,Peyrin-Biroulet L,Serrero M,et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort[J]. Alimentary Pharmacology & Therapeutics,2018,47(4):485-493.
[23]	Rogler G,Singh A,Kavanaugh A,et al. Extraintestinal manifestations of inflammatory bowel disease: Current concepts,treatment,and implications for disease management[J]. Gastroenterology,2021,161(4):1118-1132. doi: 10.1053/j.gastro.2021.07.042
[24]	Karreman M C, Luime J J, Hazes J M W, et al. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis[J]. Journal of Crohn’s and Colitis, 2017,11（5）: 631-642.
[25]	Thiebault H,Boyard-Lasselin P,Guignant C,et al. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab[J]. European Journal of Gastroenterology & Hepatology,2016,28(8):876-881.
[26]	Fiorino G,Danese S,Pariente B,et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents[J]. Autoimmunity Reviews,2014,13(1):15-19. doi: 10.1016/j.autrev.2013.06.005
[27]	Alivernini S,Pugliese D,Tolusso B,et al. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis[J]. RMD Open,2018,4(1):e000667. doi: 10.1136/rmdopen-2018-000667
[28]	Bryant R V,Winer S,Travis S P L,et al. Systematic review: histological remission in inflammatory bowel disease. Is “complete” remission the new treatment paradigm? An IOIBD initiative[J]. Journal of Crohn’s & Colitis,2014,8(12):1582-1597.
[29]	Sondag M,Verhoeven F,Guillot X,et al. “Paradoxical” arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease[J]. Joint Bone Spine,2018,85(1):133-134. doi: 10.1016/j.jbspin.2017.01.001
[30]	Üsküdar Cansu D,Üsküdar Teke H,Temel T,et al. Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? real life data[J]. Journal of the National Medical Association,2019,111(3):262-269. doi: 10.1016/j.jnma.2018.10.003
[31]	Cachen L,Nocturne G,Collins M,et al. Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF[J]. RMD open,2022,8(1):e001697. doi: 10.1136/rmdopen-2021-001697
[32]	Noordenbos T,Yeremenko N,Gofita I,et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis[J]. Arthritis and Rheumatism,2012,64(1):99-109. doi: 10.1002/art.33396
[33]	Puig L. Paradoxical reactions: Anti-tumor necrosis factor alpha agents,ustekinumab,secukinumab,ixekizumab,and others[J]. Current Problems in Dermatology,2018,53:49-63.
[34]	Onsun N,Yalcin B,Sallahoglu K,et al. Worsening of psoriatic arthritis after ustekinumab treatment[J]. American Journal of Therapeutics,2018,25(3):e381-e382. doi: 10.1097/MJT.0000000000000546
[35]	Stamell E F,Kutner A,Viola K,et al. Ustekinumab associated with flares of psoriatic arthritis[J]. JAMA Dermatology,2013,149(12):1410-1413. doi: 10.1001/jamadermatol.2013.5728
[36]	Garc í a Garc í a M J,Rivero Tirado M,Callizo M E P. Paradoxical arthritis in inflammatory bowel diasease patients on ustekinumab treatment[J]. Inflammatory Bowel Diseases,2019,25(7):e89. doi: 10.1093/ibd/izz019
[37]	De Galan C,Truyens M,Peeters H,et al. The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study[J]. Journal of Crohn’s and Colitis,2022,16(11):1676-1686.
[38]	Ottaviano G,Salvatore S,Salvatoni A,et al. Ocular manifestations of paediatric inflammatory bowel disease: A systematic review and meta-analysis[J]. Journal of Crohn’s and Colitis,2018,12(7):870-879. doi: 10.1093/ecco-jcc/jjy029
[39]	Gionchetti P,Dignass A,Danese S,et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations[J]. Journal of Crohn’s & Colitis,2017,11(2):135-149.
[40]	Vavricka S R,Brun L,Ballabeni P,et al. Frequency and risk factors for extraintestinal manifestations in the swiss inflammatory bowel disease cohort[J]. American Journal of Gastroenterology,2011,106(1):110-119. doi: 10.1038/ajg.2010.343
[41]	Iwahashi C,Ono H,Haruta M,et al. New onset or exacerbation of uveitis with infliximab: paradoxical effects?[J]. BMJ Open Ophthalmology,2019,4(1):e000250. doi: 10.1136/bmjophth-2018-000250
[42]	Clemmensen K,Akrawi N,Stawowy M. Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis[J]. Scandinavian Journal of Gastroenterology,2015,50(12):1508-1511. doi: 10.3109/00365521.2015.1063155
[43]	Garcia-Medina J J,Pastor-Grau A,del-Rio-Vellosillo M,et al. Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-year follow-up[J]. Scandinavian Journal of Gastroenterology,2016,51(6):765-766. doi: 10.3109/00365521.2015.1126855
[44]	Matet A,Daruich A,Beydoun T,et al. Systemic adalimumab induces peripheral corneal infiltrates: A case report[J]. BMC Ophthalmology,2015,15:57. doi: 10.1186/s12886-015-0047-6
[45]	Jordan D R,Park J S Y,Al-Breiki D. Acute orbital inflammation with loss of vision: a paradoxical adverse event associated with infliximab therapy for Crohn’s disease[J]. Orbit,2021,41(6):791-796.
[46]	Gîlcă G-E,Diaconescu S,Bălan G Gh,et al. Sarcoidosis associated with infliximab therapy in ulcerative colitis: A case report[J]. Medicine,2017,96(10):e6156. doi: 10.1097/MD.0000000000006156
[47]	Murdaca G,Spanò F,Contatore M,et al. Infection risk associated with anti-TNF-α agents: a review[J]. Expert Opinion on Drug Safety,2015,14(4):571-582. doi: 10.1517/14740338.2015.1009036
[48]	the BIOGEAS Study Group,Bosch X,Saiz A,et al. Monoclonal antibody therapy-associated neurological disorders[J]. Nature Reviews Neurology,2011,7(3):165-172. doi: 10.1038/nrneurol.2011.1
[49]	Brigo F,Bongiovanni L G,Cerini R,et al. Infliximab-related seizures: A first case study[J]. Epileptic Disorders,2011,13(2):214-217. doi: 10.1684/epd.2011.0439
[50]	Calafat M,Mañosa M,Ricart E,et al. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease: A cohort study of the ENEIDA registry[J]. Journal of Crohn’s & Colitis,2022,16(6):946-953.

Relative Articles(20)

Relative Articles

[1]	Hanyu ZHANG, Juan LUO, Mingzhi DONG, Qiyin CHEN, Fengrui ZHANG, Rui GUO, Junying TONG, Yinglei MIAO. Retrospective Cohort Study of Infliximab and Vederizumab in the Treatment of Moderate-to-severe Ulcerative Colitis. Journal of Kunming Medical University, 2025, 46(4): 1-9.
[2]	Hanyu ZHANG, Juan LUO, Mingzhi DONG, Qiyin CHEN, Fengrui ZHANG, Rui GUO, Junying TONG, Yinglei MIAO. Retrospective Cohort Study of Infliximab and Vederizumab in the Treatment of Moderate-to-severe Ulcerative Colitis. Journal of Kunming Medical University, 2024, 45(10): 36-44. doi: 10.12259/j.issn.2095-610X.S20241006
[3]	Bo LI, Yang SUN, Yinglei MIAO. Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease. Journal of Kunming Medical University, 2024, 45(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20240401
[4]	Zhongshun NIE, Yinglei MIAO. Prospects of Fecal Microbiota Transplantation for Inflammatory Bowel Disease in the Context of Biological Agents. Journal of Kunming Medical University, 2024, 45(10): 147-154. doi: 10.12259/j.issn.2095-610X.S20241023
[5]	Shunhang YANG, Jiongming LI, Jianhe LIU, Guang WANG, Pei LI. Progress in Pathogenesis and Treatment of Enteric Hyperoxaluria. Journal of Kunming Medical University, 2022, 43(7): 152-155. doi: 10.12259/j.issn.2095-610X.S20220734
[6]	Yanqin RUAN, Maojuan LI, Limei HE, Ying SONG, Qiaoyun HUANG, Ying CHEN, Chang LIU. Screening of Special Abnormal Module Items in PRO Scale for Patients with Inflammatory Bowel Disease.. Journal of Kunming Medical University, 2022, 43(3): 37-43. doi: 10.12259/j.issn.2095-610X.S20220310
[7]	Rong LIU, Yang SUN, Fameng LUO, Dezhi TAO, Haiyan ZHANG. Correlation between the Acceptance of Illness and Quality of Life in Patients with Inflammatory Bowel Disease. Journal of Kunming Medical University, 2022, 43(5): 173-178. doi: 10.12259/j.issn.2095-610X.S20220507
[8]	Xing LIU, Hai-wen LI, Hong-li HUANG, Lin-jun SHEN, Le ZHANG, Xiang-fang LIU, Wen-lin ZHANG, Lu WANG. Effects of Probiotics Enhanced Enteral Nutrition on Gastrointestinal Function and Cytokines in Patients with Severe Acute Pancreatitis. Journal of Kunming Medical University, 2021, 42(11): 81-86. doi: 10.12259/j.issn.2095-610X.S20211116
[9]	Qian JIANG, Yu SUN, Li-jun HUO, Ya-yan LEI, Luo-wei PEI. Antibacterial Effect of Slightly Acidic Electrolyzed Water on Enterococcus faecalis Biofilm in Root Canal in Vitro. Journal of Kunming Medical University, 2021, 42(3): 5-9. doi: 10.12259/j.issn.2095-610X.S20210303
[10]	Pu XIONG, Zun-yue ZHANG, Kun-hua WANG. Intestinal Barrier Damage Caused by Drug Dependence. Journal of Kunming Medical University, 2021, 42(1): 161-166. doi: 10.12259/j.issn.2095-610X.S20210131
[11]	Xiang Ying Ying , Yu Hong Bin , Zhou Jing , Yang Xiang Hong , Song Fei , Wei Yun Lin , Ji Xiu Ling . . Journal of Kunming Medical University, 2020, 41(05): 46-51.
[12]	Huang Zhi Guo , Yin Wei , Yan Yi . . Journal of Kunming Medical University, 2019, 40(08): 6-11.
[13]	Zhang An Xing , Wu Jing , Sun Yang , Miao Ying Lei . . Journal of Kunming Medical University, 2018, 39(09): 128-132.
[14]	Sun Yang . . Journal of Kunming Medical University,
[15]	Ye Shi Hua . . Journal of Kunming Medical University, 2014, 35(05): 1-1.
[16]	Yang Shao Fen . . Journal of Kunming Medical University,
[17]	Ai Jia . . Journal of Kunming Medical University,
[18]	Liu Yan . . Journal of Kunming Medical University,
[19]	Li Min Li . . Journal of Kunming Medical University,
[20]	Yang Yang . . Journal of Kunming Medical University,